Immunome (IMNM) Stock Statistics & Valuation Metrics

Immunome has a market cap or net worth of $894.82M. The enterprise value is $545.31M.

Immunome has 87,045,006 shares outstanding. The number of shares has decreased by -2.65% in one year.

Immunome’s return on equity (ROE) is -1.62 and return on invested capital (ROIC) is -164.41%.

The current PE Ratio of Immunome is ―. Immunome’s PEG ratio is ―.

In the last 12 months, Immunome had revenue of 9.04M and earned -292.96M in profits. Earnings per share was -5.00.

In the last 12 months, operating cash flow was -178.68M and capital expenditures -7.48M, giving a free cash flow of -186.17M billion.

Immunome pays an annual dividend of ―, resulting in a dividend yield of ―

Immunome upcoming earnings date is Nov 17, 2025, After Close (Confirmed).

Immunome as a current ratio of 4.08, with Debt / Equity ratio of 1.54%

In the past 12 months, Immunome has paid 0.00 in taxes.

Immunome EV to EBITDA ratio is -3.20, with an EV/FCF ratio of -4.10.

Immunome has $268.04M in cash and marketable securities with $4.14M in debt, giving a net cash position of -$263.89M billion.

Gross margin is 100.00%, with operating margin of -3382.37%, and net profit margin of -3240.38%.

The average price target for Immunome is $22.38, which is 11.43% higher than the current price. The consensus rating is Strong Buy